Cargando…

Sequential Administration of PCV13 Followed by PPSV23 Results in a More Robust Immune Response in PPSV23-Naïve Adults Age 60–64 Years

BACKGROUND: Recommendations for adult pneumococcal immunization generally specify the use of PCV13 first, followed by PPSV23, when administered sequentially, for prevention of pneumococcal disease. This is supported by observations of reduced functional opsonophagocytic assay (OPA) antibody titers i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chilson, Erica, Atkinson, Bruce, Hall-Murray, Cassandra, Snow, Vincenza, Schmoele-Thoma, Beate, Isturiz, Raúl E, Scott, Daniel A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631263/ http://dx.doi.org/10.1093/ofid/ofx163.1200

Ejemplares similares

1098 The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions
por: Schmoele-Thoma, Beate, et al.
Publicado: (2014)

Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients
por: Mülling, Nils, et al.
Publicado: (2023)

Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients
por: Migita, Kiyoshi, et al.
Publicado: (2015)

The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
por: Feldman, Charles, et al.
Publicado: (2020)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

Influenza, PCV13, and PPSV23 Vaccination Rates Among Inflammatory Bowel Disease Patients With Additional Co-Morbidities as per CDC Recommendations
por: Jordan, Ariel, et al.
Publicado: (2021)

Factors associated with PPSV23 coverage among older adults in Japan: a nationwide community-based survey
por: Murakami, Yoshitaka, et al.
Publicado: (2019)

23-valent polysaccharide vaccine (PPSV23)-targeted serotype-specific identification of Streptococcus pneumoniae using the loop-mediated isothermal amplification (LAMP) method
por: Lee, Jiwon, et al.
Publicado: (2021)

Social capital and pneumococcal vaccination (PPSV23) in community-dwelling older Japanese: a JAGES multilevel cross-sectional study
por: Iwai-Saito, Kousuke, et al.
Publicado: (2021)

A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older
por: Kawakami, Kenji, et al.
Publicado: (2019)

Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering
por: Lanz, Alessandra M., et al.
Publicado: (2022)

A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician’s attitude
por: Nakamura, Atsushi, et al.
Publicado: (2020)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
por: Chilson, Erica, et al.
Publicado: (2020)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Decision-making for PCV in adults
por: McLaughlin, John M., et al.
Publicado: (2018)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
por: Hurley, Donald, et al.
Publicado: (2020)

1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age
por: Lapidot, Rotem, et al.
Publicado: (2020)

1442. Pneumonia Hospitalizations Averted With 13-Valent Pneumococcal Conjugate Vaccination of Adults Aged 18–64 Years With Diabetes in the United States
por: Suaya, Jose, et al.
Publicado: (2018)

Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
por: van der Linden, Mark, et al.
Publicado: (2015)

1434. Cost-Effectiveness of Sequencial Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23 Valent Polysaccharide Vaccine (PPV23) in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Antibiotic Prescription Rates in Children <24 Months Old Following PCV7/PCV13 Sequential Implementation
por: Dagan, Ron, et al.
Publicado: (2017)

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
por: Baxter, Roger, et al.
Publicado: (2015)

Cloning and Expression of the Tibetan Pig Interleukin-23 Gene and Its Promotion of Immunity of Pigs to PCV2 Vaccine
por: Xiao, Yongle, et al.
Publicado: (2020)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
por: Thompson, Allison R., et al.
Publicado: (2018)

Sequential interactions with Sec23 control the direction of vesicle traffic
por: Lord, Christopher, et al.
Publicado: (2011)

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
por: Cordonnier, Catherine, et al.
Publicado: (2015)

One Dose of a Novel Vaccine Containing Two Genotypes of Porcine Circovirus (PCV2a and PCV2b) and Mycoplasma hyopneumoniae Conferred a Duration of Immunity of 23 Weeks
por: Mancera Gracia, José Carlos, et al.
Publicado: (2021)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions
por: Opriessnig, Tanja, et al.
Publicado: (2017)

Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study
por: Ignatova, Galina L., et al.
Publicado: (2021)

Estimates and trends of zero vegetable or fruit consumption among children aged 6–23 months in 64 countries
por: Allen, Courtney K., et al.
Publicado: (2023)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
por: Vietri, Jeffrey, et al.
Publicado: (2019)

Genome Sequence of Human Papillomavirus 23 Strain HPV-23/Lancaster/2015
por: Atkinson, Kate V., et al.
Publicado: (2017)

Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia
por: Roca, Anna, et al.
Publicado: (2015)

2727. Numbers Needed to Vaccinate for Prevention of Adult Pneumonia with Pneumococcal Conjugate Vaccine: Which Values Should Determine Policy?
por: Gessner, Bradford D, et al.
Publicado: (2019)

CERN Bulletin Issue No. 23-23/2020
Publicado: (2020)

Good long-term outcome of synovectomy in advanced stages of the rheumatoid elbow: 64 elbows followed for 10–23 years
por: Ishii, Katsushi, et al.
Publicado: (2012)

Molecular interactions of FGF23 and PTH in phosphate regulation
por: Lanske, Beate, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_69m4lhbk5jh37fkqi5sqhdlb8m